Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 3: 533 - 541

DOI: https://doi.org/10.19852/j.cnki.jtcm.2023.03.003

Efficacy of Buzhong Yiqi decoction (补中益气汤) on benign prostatic hyperplasia and its possible mechanism

  • Lihua JIA ,
  • Haodan KUANG ,
  • Yuan XU
Expand
  • 1 Department of urology, Jinhua Hospital of TCM, Jinhua 321000, China
    2 Zhejiang Chinese Medical University college of pharmacy, Hangzhou 310053, China
    3 Ningbo medical center Lihuili Hospital, Ningbo 315100, China

Received date: 2021-10-12

  Accepted date: 2022-01-27

  Online published: 2023-04-28

Fold

Abstract

OBJECTIVE: To explored the mechanism of Buzhong Yigi decoction (补中益气汤 BZYQD) in inhibiting prostatic cell proliferation effect.

METHODS: The compounds of BZYQD consisted with eight herbs were searched in TCMSP databases and the putative targets of BZYQD were collected in Drugbank database. Then, “Benign prostatic hyperplasia” (BPH) was used to find the targets based on the GeneCards, Online Mendelian Inheritance in Man (OMIM) and Therapeutic Target Database (TTD) databases, and they were further used to collect further collect the intersection targets between BZYQD and BPH by counter-selection. Next, Herb-Compound-Target-Disease network was constructed by Cytoscape software and protein interaction network was built by Search tool for recurring instances of neighbouring genes (STRING) database. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment were analyzed by Database for Annotation, Visualization and Integrated Discovery (DAVID) database to predict the mechanism of the intersection targets. Mitogen activated protein kinase 8 (MAPK8), interleukin 6 (IL-6) and quercetin were chosen to perform molecular docking. Then 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay was to detect the viability of BPH-1 (BPH epithelial cell line) by treated with quercetin at the concentrations of 15, 30, 60, 120 μM for 12, 24, 48, 72 h. The production of IL-6, tumor necrosis factor-α (TNF-α), IL-1β and were mRNA expression detected by enzyme-linked immunosorbent assay kit and quantitative real-time polymerase chain reaction. Western blot was used to detect the expression of phospho-p38 mitogen-activated protein kinase (p-P38) and matrix metalloprotein-9 (MMP-9).

RESULTS: A total 151 chemical ingredients of 8 herbs and 1756 targets in BZYQD, 105 common targets of BZYQD and BPH which mainly involving with MAPK8, IL-6, and so on. GO enrichment analysis got 352 GO entries (P <0.05) which included 208 entries of biological process, 64 entries of cell component and 80 entries of molecular function. KEGG pathway Enrichment analyses got 20 significant pathways which mainly involved with MAPK signaling way. MTT assay indicated quercetin inhibited the viability of BPH-1 cells by time-and dose-dependent manner. Quercetin decreased the IL-6, TNF-α and IL-1β production and mRNA expression, and the expression of p-P38 and MMP-9 were also obviously reduced after treated with quercetin.

CONCLUSIONS: BZYQD inhibited BPH through suppressing inflammatory response which might involving with regulating the MAPK signaling way.

Key words： quercetin; prostatic hyperplasia; network pharmacology; Buzhong Yiqi decoction

Cite this article

Lihua JIA , Haodan KUANG , Yuan XU . Efficacy of Buzhong Yiqi decoction (补中益气汤) on benign prostatic hyperplasia and its possible mechanism[J]. Journal of Traditional Chinese Medicine, 2023 , 43(3) : 533 -541 . DOI: 10.19852/j.cnki.jtcm.2023.03.003

References

[1] Hanumantharaju BK, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Manjunatha R. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol 2016; 48: 134-40.
[2] Foo KF. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J Urol, 2019; 37: 1293-6.
[3] Renggli M, Padrutt I, Michel E, Reichler I. Benign prostatic hyperplasia: treatment options in the dog. Schweiz Arch Tierheilkd 2010; 152: 279-84.
[4] Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5alpha-reductase inhibitors. JAMA Intern Med 2017; 177: 683-91.
[5] Strope SA, Yang L, Nepple KG, Andriole GL, Owens PL. Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasia. J Urol 2012; 187: 1341-5.
[6] Nishizawa O, Yoshida M, Takeda M, et al. Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies. Int J Urol 2015; 22: 378-84.
[7] Chen W, Huang X, Peng A, et al. Kangquan recipe regulates the expression of BAMBI protein via the TGF-beta/Smad signaling pathway to inhibit benign prostatic hyperplasia in rats. Evid Based Complement Alternat Med 2019; 2019: 1-12.
[8] Yuan Y, Yang J, Zhu W, et al. Qianlongtong inhibits proliferation and induces apoptosis of hyperplastic prostate cells. Am J Mens Health 2018; 12: 1548-53.
[9] Wang Y, Yu W, Shi C, et al. Network pharmacology of Yougui pill combined with Buzhong Yiqi decoction for the treatment of sexual dysfunction. Evid Based Complement Alternat Med 2019; 2019: 1-10.
[10] Chen Y, Shergis JL, Wu L, et al. A systematic review and meta-analysis of the herbal formula Buzhong Yiqi Tang for stable chronic obstructive pulmonary disease. Complementary Therapies in Medicine 2016; 2016: 94-108.
[11] Deng D, Chen Z, Jia L, et al. Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial. Trials 2019; 20: 1-8.
[12] Chen Z, Huang H, Chen QY. Effect of modified Buzhong Yiqi decoction combined with pelvic floor muscle exercise-biofeedback-electrical stimulation on early stage postpartum pelvic floor dysfunction. Zhong Guo Zhong Yao Za Zhi 2018 43: 2391-5.
[13] Jarrell JT, Gao L, Cohen DS, Huang X. Network medicine for Alzheimer's disease and Traditional Chinese Medicine. Molecules, 2018; 23: 1143.
[14] Zhang RZ, Yu SJ, Bai H, Ning K. TCM-Mesh: The database and analytical system for network pharmacology analysis for TCM preparations. Sci Rep 2017; 7: 2821.
[15] Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014; 6: 13.
[16] Sheng S, Wang J, Wang L, et al. Network pharmacology analyses of the antithrombotic pharmacological mechanism of Fufang Xueshuantong Capsule with experimental support using disseminated intravascular coagulation rats. J Ethnopharmacol, 2014; 154: 735-44.
[17] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13: 2498-504.
[18] Kim SS, Kim JH, Han IH, Ahn MH, Ryu JS. Inflammatory responses in a benign prostatic hyperplasia epithelial cell line (BPH-1) infected with Trichomonas vaginalis. Korean J Parasitol 2016; 54: 123-32.
[19] Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 2015; 22: 1-6.
[20] Ju WJ, Zhao ZK, Chen SL, et al. Buzhong Yiqi decoction Protects against loperamide-induced constipation by regulating the arachidonic acid pathway in rats. Front Pharmacol 2020; 2020: 423.
[21] Murakami Y. Clinical effect of hotyuekkito (Buzhong Yiqi Tang) on symptoms due to renal ptosis and stress incontinence. Hinyokika Kiyo, 1988; 34: 1841-3.
[22] Furuya Y, Akashi T, Fuse H. Effect of Bu-zhong-yi-qi-tang on seminal plasma cytokine levels in patients with idiopathic male infertility. Arch Androl, 2004; 50: 11-4.
[23] Chen G, Huang C, Liu Y, et al. Network pharmacology approach to uncover the potential mechanism of Yinchensini Decoction. Evid Based Complement Alternat Med 2018; 2018: 1-14.
[24] Li Y, Yao J, Han C, et al. Quercetin, inflammation and immunity. Nutrients 2016; 8:167.
[25] Park KH, Yin J, Yoon KH, Hwang YJ, Lee MW. Antiproliferative effects of new dimeric ellagitannin from cornus alba in prostate cancer cells including apoptosis-related s-phase arrest. Molecules 2016; 21: 137.
[26] Yin J, Heo JH, Hwang YJ, Le TT, Lee MW. Inhibitory activities of phenolic compounds isolated from adina rubella leaves against 5alpha-reductase associated with benign prostatic hypertrophy. Molecules 2016; 21:887.
[27] Elberry AA, Mufti S, Al-Maghrabi J, et al. Immunomodulatory effect of red onion (Allium cepa Linn) scale extract on experimentally induced atypical prostatic hyperplasia in wistar rats. Mediators Inflamm 2014; 2014: 640746.
[28] Nunzio CD, Salonia A, Gacci M, et al. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia World J Urol 2010; 38: 2771-9.
[29] Rodriguez-Berriguete G, Prieto A, Fraile B, et al. Relationship between IL-6/ERK and NF-kappa B: a study in normal and pathological human prostate gland. Eur Cytokine Netw 2010; 21: 241-50.
[30] Funahashi Y, Majima T, Matsukawa Y, et al. Intraprostatic Reflux of urine induces inflammation in a rat. Prostate 2017; 77: 164-72.
[31] Dong-Hyun Y, Jinbong P, Hye-Lin K, et al. Berberine improves benign prostatic hyperplasia via suppression of 5 alpha reductase and extracellular signal-regulated kinase in vivo and in vitro. Front Pharmacol 2018; 9: 773.
[32] Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 2013; 4: 342-59.
[33] Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25-9.
[34] Gong F, Zhang Y, Lin J, et al. 1-(5-Bromo-2-hydroxy-4-methoxyphenyl) ethanone [SE1] inhibits MMP-9 expression by regulating NF-kappa B and MAPKs signaling pathways in HT1080 human fibrosarcoma cells. Evid Based Complement Alternat Med 2018; 2018: 1-9.
[35] Hamdy F, Fadlon E, Cottam D, et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1994; 69: 177-82.
[36] Zhang S, Wei G, Ren TT, et al. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase. Anticancer Drugs 2012; 23: 108-18.
[37] Babichenko II, Andriukhin MI, Pulbere S, et al. Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma. Int J Clin Exp Pathol 2014; 7: 9090-8.
[38] Eberhardt W, Huwiler A, Beck KF, Walpen S, Pfeilschifter J. Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J Immunol 2000; 165: 5788-97.
Options
Outlines

/

〈 〉